Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

3.15USD
21 Feb 2017
Change (% chg)

$0.05 (+1.61%)
Prev Close
$3.10
Open
$3.10
Day's High
$3.15
Day's Low
$3.10
Volume
139,778
Avg. Vol
209,987
52-wk High
$4.50
52-wk Low
$2.40

ACRX.O

Chart for ACRX.O

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 2.81
Market Cap(Mil.): $142.80
Shares Outstanding(Mil.): 45.33
Dividend: --
Yield (%): --

Financials

  ACRX.O Industry Sector
P/E (TTM): -- 46.79 29.35
EPS (TTM): -0.98 -- --
ROI: -41.11 -3.72 12.97
ROE: -203.62 4.91 14.11

BRIEF-Acelrx Pharmaceuticals appoints Vincent Angotti as CEO

* Acelrx Pharmaceuticals appoints Vincent J. Angotti chief executive officer

Feb 16 2017

BRIEF-Acelrx Pharma says amended loan and security deal with Hercules Tech II and Hercules Capital Inc

* Among other things, amendment extends interest-only period from October 1, 2016 to April 1, 2017 - SEC filing

Oct 03 2016

BRIEF-AcelRx Pharmaceuticals initiates late-stage study of its painkiller

* Initiates phase 3 study of Zalviso in patients with moderate-to-severe acute post-operative pain Source text for Eikon: Further company coverage:

Sep 27 2016

AcelRx's opioid painkiller succeeds in key study

AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

Sep 15 2016

UPDATE-1-AcelRx's opioid painkiller succeeds in key study

Sept 15 AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

Sep 15 2016

BRIEF-Acelrx reports positive results for ARX-04 in Phase 3 registration trial

* Reports positive results for ARX-04 (sufentanil sublingual tablet, 30 mcg), including in elderly patients and patients with organ impairment, in third Phase 3 registration trial, SAP303

Sep 15 2016

BRIEF-Acelrx Pharmaceuticals posts results from phase 3 study of ARX-04

* Acelrx pharmaceuticals presents results from phase 3 study of ARX-04 in the emergency department at the international society for burn injuries

Aug 29 2016

More From Around the Web

Earnings vs. Estimates